- Patients with NSCLC and idiopathic pulmonary fibrosis (IPF) often have a different disease presentation at diagnosis, are less likely to receive therapy with advanced disease, and have poorer outcomes compared with patients without IPF.
Why this matters
- Patients with IPF have a 10%-30% chance of developing lung cancer compared with a risk of 6% in the general population.
- 54,453 patients with stage I-IV NSCLC from the Surveillance, Epidemiology, and End Results database.
- Funding: Stony Wold Herbert Fund Inc.
- 855 patients (2%) had IPF.
- Patients with IPF were more often diagnosed with stage I disease (31% vs 25%; P<.01 and with smaller tumors size vs mm p>
- Patients with IPF had a greater proportion of squamous carcinoma (46% vs 35%; P<.01 and lower-lobe tumors vs p>
- Patients with IPF with stage III-IV lung cancer were less likely to undergo treatment than advanced stage patients without IPF (OR, 0.82; 95% CI, 0.68-0.99).
- Patients with IPF had significantly poorer OS (aHR, 1.35; 95% CI, 1.26-1.45) and cancer-specific survival (CSS; aHR, 1.32; 95% CI, 1.21-1.44).
- Survival was poorer with receipt and nonreceipt of stage-appropriate therapy in stratified analysis.
- No patient-specific data.